Moreover, longitudinal monitoring of TIL therapy in melanoma patients with antigen peptide-MHC (pMHC) multimers revealed increased frequency (up to 750-fold) and long-term (>6 months) persistence of antigen-specific T cells in cohorts of responding patients [91]. Here, HLA-C is linked to melanoma.